Coya Therapeutics, Inc. (COYA) · Oct 14, 2026 · Other events

Coya Therapeutics delays FTD trial as ALS extension begins

ALS prioritized; FTD delayed — OLE begins November 2026; FTD trial shifts from 2H 2026 to 2027

Coya Therapeutics’ clinical-trial update adds an ALS open-label extension in November, but shifts its FTD Phase 2 start from 2026 to 2027.

Coya is a clinical-stage biotech building regulatory-T-cell therapies, with COYA 302 now centered on its fully enrolled Phase 2/3 ALS program and FTD as the next indication.

The filing deepens the company’s commitment to ALS rather than adding efficacy evidence. Coya plans to begin an open-label extension in November for participants completing the 48-week ALSTARS course, allowing continued treatment and longer-term safety and efficacy collection. 〔0〕 This is useful for durability and tolerability evidence, but it does not change the trial’s blinded primary readout or establish that COYA 302 works.

The trade-off is a real delay to the pipeline’s second clinical program. Before this filing, management had described the FTD study as an imminent 2026 activity while targeting ALSTARS topline data in the first quarter of 2027. The company now says the FTD Phase 2 trial will start in 2027 because resources are being concentrated on ALS execution and near-term ALSTARS milestones. 〔1〕

The shift does not appear to reflect an immediate financing problem. Coya kept its cash-runway outlook unchanged, saying existing resources should fund operations into the second half of 2027 and beyond the anticipated ALSTARS topline readout. 〔2〕

Bottom line: This is a mixed clinical-development update: Coya is adding potentially valuable long-term ALS data and concentrating resources on its lead trial, but it is accepting a slower expansion into FTD. The near-term story remains the ALSTARS readout, not a new efficacy signal.

What to watch next

ALSTARS topline data, Q1 2027

Original filing on SEC EDGAR

Coya Therapeutics delays FTD trial as ALS extension begins | COYA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.